Novel nanomedicines to overcome cancer multidrug resistance

Su, Zhenwei; Dong, Shaowei; Zhao, Shan‐Chao; Liu, Kaisheng; Tan, Yao; Jiang, Xingyu; Assaraf, Yehuda G.; Qin, Bo; Chen, Zhe-Sheng; Zou, Chang

doi:10.1016/j.drup.2021.100777

Cited by 103 publications

(55 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the LAP nanoplatforms, as carriers for delivering chemotherapeutic agents, have been designed to overcome side effects and MDR by improving drug water-solubility, colloidal stability, controlled drug release properties, tumor-targeting specificity, and multidrug combinations. 44,45…”

Section: Lap Nanoplatforms For Cancer Therapymentioning

confidence: 99%

LAPONITE® nanodisk-based platforms for cancer diagnosis and therapy

Guo

et al. 2022

Mater. Adv.

View full text Add to dashboard Cite

show abstract

Section: Lap Nanoplatforms For Cancer Therapymentioning

confidence: 99%

LAPONITE® nanodisk-based platforms for cancer diagnosis and therapy

Guo

et al. 2022

Mater. Adv.

View full text Add to dashboard Cite

show abstract

“…Thus, using a combination of drugs and altering their subcellular distribution can provide new ideas and methods for tapping the therapeutic potential of classical drugs. In addition, the KLA peptide interacts rapidly with the cell membrane, which may help it bypass multidrug resistance and be effective against drug-resistant TNBC [ 55 , 56 , 57 , 58 ]. The good efficacy and safety of KLA-5-FU/PTX Lps shown here justify further pharmacokinetics and pharmacodynamics studies in comparison with injectable PTX liposomes and compound injectable polyphase 5-FU liposomes, which may bring the Lps closer to use in the clinic.…”

Section: Discussionmentioning

confidence: 99%

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment

Chen

Jiang

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

In this research, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel (KLA-5-FU/PTX Lps) were developed, and their antitumor activity against triple-negative breast cancer (TNBC) was evaluated. KLA-5-FU/PTX Lps were prepared using the thin-film dispersion method, and their in vitro anticancer efficacy was assessed in human breast cancer cells (MDA-MB-231). An MDA-MB-231 tumor-bearing mouse model was also established to evaluate their antitumor efficacy in vivo. KLA-5-FU/PTX Lps showed enhanced cytotoxicity against MDA-MB-231 cells, improved drug delivery to mitochondria, and induced mitochondria-mediated apoptosis. The modified liposomes also showed favorable antitumor activity in vivo due to their strong ability to target tumors and mitochondria. The liposomes showed no obvious systemic toxicity. Our results suggest that KLA-5-FU/PTX Lps are a promising system with which to target the delivery of antitumor drugs to mitochondria as a treatment for TNBC.

show abstract

“…(6) The conversion of anti-cancer drugs to non-active ingredients. (7) The drug is captured and degraded by lysosomes [ 215 ]. MTKIs resistance usually occurs within one year of treatment.…”

Section: Nanotechnology Fights Mtkis Resistancementioning

confidence: 99%